At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CNSP CNS Pharmaceuticals, Inc.
Pre-Market Trading 11-22 05:26:02 EST
0.1300
+0.0064
+5.18%
盘前0.1250
-0.0050-3.85%
05:14 EST
High0.1450
Low0.1270
Vol33.64M
Open0.1320
D1 Closing0.1236
Amplitude14.56%
Mkt Cap7.47M
Tradable Cap7.33M
Total Shares57.49M
T/O4.74M
T/O Rate59.66%
Tradable Shares56.38M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.